Shattuck Labs Reports First Quarter 2022 Financial Results and Recent Business Highlights
12 mai 2022 07h00 HE
|
Shattuck Labs, Inc.
– Dose escalation ongoing in Phase 1 clinical trial of SL-172154 in platinum-resistant ovarian cancer; combination trial with liposomal doxorubicin on track to begin in 2H’2022; full dose-escalation...
Shattuck Labs Presents Preclinical Data at the 2022 American Association for Cancer Research (AACR) Annual Meeting
08 avr. 2022 16h55 HE
|
Shattuck Labs, Inc.
- SL-9258 (TIGIT-Fc-LIGHT) combined with anti-PD(L)1 broadened anti-tumor activity of the checkpoint antibodies in aggressive CPI-resistant tumors - - Butyrophilin heterodimeric fusion proteins from...
Shattuck Labs Announces Participation in Upcoming 21st Annual Needham Virtual Healthcare Conference
05 avr. 2022 17h00 HE
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, April 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins...
Shattuck Labs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
15 mars 2022 07h00 HE
|
Shattuck Labs, Inc.
– Presented positive initial dose-escalation clinical data for SL-172154, including high target occupancy, dose-dependent immune activation, and unique safety profile in heavily pretreated cancer...
Shattuck Labs to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting
09 mars 2022 08h21 HE
|
Shattuck Labs, Inc.
AUSTIN, Texas and DURHAM, N.C., March 09, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...
Shattuck Labs Announces Participation in Upcoming March Conferences
02 mars 2022 08h39 HE
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, March 02, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs Announces Participation in Upcoming 11th Annual SVB Leerink Global Healthcare Conference
09 févr. 2022 17h00 HE
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs Announces Participation in Upcoming January Investor Conferences
05 janv. 2022 08h30 HE
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as...
Shattuck Labs to Present at TIGIT Therapies Digital Summit 2021
02 déc. 2021 07h17 HE
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of...
Shattuck Labs Announces Preliminary Clinical Data from Ongoing Phase 1 Clinical Trials of ARC Fusion Proteins SL-172154 and SL-279252
09 nov. 2021 08h00 HE
|
Shattuck Labs, Inc.
– SL-279252 (PD1-Fc-OX40L) demonstrates anti-tumor activity and evidence of dose-dependent immune activation in heavily pretreated, checkpoint experienced patients – – SL-172154 (SIRPα-Fc-CD40L)...